Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Luke Miels
Biotech
Why the next blockbuster in GSK CEO's sights could be in cancer
Under GSK’s new strategy of trying to outdo established blockbusters, CEO Luke Miels told Fierce that oncology may offer the most tempting targets.
James Waldron
Apr 29, 2026 7:16am
GSK's new CEO looking for $2B-$4B deals 'hiding in plain sight'
Feb 4, 2026 7:25am
Fierce Pharma
GSK's Emma Walmsley to step down as CEO in shock move
Sep 29, 2025 3:39am
JPM25: M&A strategist GSK acquires IDRx for $1B upfront
Jan 13, 2025 2:00am
After Merck's cough drama, GSK knew what to do with Bellus asset
Nov 30, 2023 8:00am
Sierra wanted a partnership, but GSK wanted the store
May 3, 2022 11:04am
Fierce Pharma
Fierce Pharma
Fierce Pharma
Fierce Pharma
